# Moderna (MRNA) — Analyst Forecast

MRNA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mrna/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 6 | 15 | 6 | 27 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $77.00 | $115.63 | $180.00 | 8 |

Last price $236.50 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | Goldman Sachs | Maintained | Neutral | $137.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | $95.00 |
| Sep 30, 2026 | Citigroup | Downgraded | Neutral → Sell | $80.00 |
| Sep 3, 2026 | Rothschild & Co | Downgraded | Neutral → Sell | $81.00 |
| Aug 28, 2026 | Argus Research | Upgraded | Hold → Buy | $180.00 |
| Aug 25, 2026 | Wolfe Research | Upgraded | Underperform → Peer Perform | — |
| Aug 24, 2026 | Barclays | Maintained | Equal-Weight | $125.00 |
| Aug 21, 2026 | JP Morgan | Maintained | Underweight | $77.00 |
| Aug 20, 2026 | Morgan Stanley | Maintained | Equal-Weight | $89.00 |
| Aug 20, 2026 | UBS | Maintained | Neutral | $150.00 |
| Aug 20, 2026 | Goldman Sachs | Maintained | Neutral | $120.00 |
| Aug 19, 2026 | William Blair | Upgraded | Market Perform → Outperform | — |
| Aug 3, 2026 | Citigroup | Maintained | Neutral | $60.00 |
| Jul 21, 2026 | Goldman Sachs | Maintained | Neutral | $67.00 |
| Jul 8, 2026 | Morgan Stanley | Maintained | Equal-Weight | $39.00 |
| Jul 7, 2026 | B of A Securities | Maintained | Underperform | $38.00 |
| Jul 7, 2026 | RBC Capital | Maintained | Sector Perform | $45.00 |
| Jun 26, 2026 | Piper Sandler | Maintained | Overweight | $77.00 |
| Jun 8, 2026 | B of A Securities | Maintained | Underperform | $34.00 |
| May 4, 2026 | RBC Capital | Maintained | Sector Perform | $38.00 |

## Frequently Asked Questions

### What is the price target for MRNA stock?

The average 12-month analyst price target for Moderna (MRNA) is $115.63, with a high estimate of $180.00 and a low of $77.00, across 8 analysts.

### Is MRNA a buy, sell, or hold?

Analysts covering Moderna currently average a Hold rating: 6 buy, 15 hold and 6 sell, from 27 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for MRNA?

The average price target of $115.63 implies 51.11% downside from the last price of $236.50.

### What is the latest analyst rating on MRNA?

On Oct 15, 2026, Goldman Sachs maintained Moderna at Neutral with a price target of $137.00.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [NVAX](https://www.lighthorse.io/tickers/nvax) — Novavax, Inc. - Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares
- [OCGN](https://www.lighthorse.io/tickers/ocgn) — Ocugen, Inc. - Common Stock
- [TSLA](https://www.lighthorse.io/tickers/tsla) — Tesla, Inc.  - Common Stock
- [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock
- [HOOD](https://www.lighthorse.io/tickers/hood) — Robinhood Markets, Inc. - Class A Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).